Back to Search Start Over

Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial

Authors :
El Messaoudi, S.
Nederlof, R.
Zuurbier, C.J.
Swieten, H.A. van
Pickkers, P.
Noyez, L.
Dieker, H.J.
Coenen, M.J.H.
Donders, A.R.T.
Vos, A.
Rongen, G.A.P.J.M.
Riksen, N.P.
El Messaoudi, S.
Nederlof, R.
Zuurbier, C.J.
Swieten, H.A. van
Pickkers, P.
Noyez, L.
Dieker, H.J.
Coenen, M.J.H.
Donders, A.R.T.
Vos, A.
Rongen, G.A.P.J.M.
Riksen, N.P.
Source :
Lancet Diabetes & Endocrinology; 615; 623; 2213-8587; 8; 3; ~Lancet Diabetes & Endocrinology~615~623~~~2213-8587~8~3~~
Publication Year :
2015

Abstract

Contains fulltext : 155124.pdf (publisher's version ) (Closed access)<br />BACKGROUND: During coronary artery bypass graft (CABG) surgery, ischaemia and reperfusion damage myocardial tissue, and increased postoperative plasma troponin concentration is associated with a worse outcome. We investigated whether metformin pretreatment limits cardiac injury, assessed by troponin concentrations, during CABG surgery in patients without diabetes. METHODS: We did a placebo-controlled, double-blind, single-centre study in an academic hospital in Nijmegen (Netherlands) in adult patients without diabetes undergoing an elective on-pump CABG procedure. We randomly assigned patients (1:1) in blocks of ten via a computer-generated randomisation sequence to either metformin hydrochloride (500 mg three times per day) or placebo (three times per day) for 3 days before surgery. The last dose was given roughly 3 h before surgery. Patients, investigators, trial staff, and the statistician were all masked to treatment allocation. The primary endpoint was the plasma concentration of high-sensitive troponin I at 6, 12, and 24 h postreperfusion after surgery, analysed in the per-protocol population with a mixed-model analysis using all these timepoints. Secondary endpoints included the occurrence of clinically relevant arrhythmias within 24 hours after reperfusion, the need for inotropic support, time to detubation, duration of stay in the intensive-care unit, and postoperative use of insulin. This study is registered with ClinicalTrials.gov, number NCT01438723. FINDINGS: Between Nov 8, 2011, and Nov 22, 2013, we randomly assigned 111 patients to treatment (57 to metformin and 54 to placebo). Five patients dropped out from the metformin group, and six from the placebo group. 52 patients in the metformin group and 48 patients in the placebo group were included in the per-protocol analysis. Geometric mean high-sensitivity troponin I increased from 0 mug/L to 3.67 mug/L (95% CI 3.06-4.41) with metformin and to 3.32 mug/L (2.75-4.01) with placebo at 6 h after reperfusio

Details

Database :
OAIster
Journal :
Lancet Diabetes & Endocrinology; 615; 623; 2213-8587; 8; 3; ~Lancet Diabetes & Endocrinology~615~623~~~2213-8587~8~3~~
Publication Type :
Electronic Resource
Accession number :
edsoai.on1247193980
Document Type :
Electronic Resource